Iliac Stent Market: as Getinge's iCast expands from occlusive disease into aneurysmal bridging indications and BD advances its Revello covered stent from IDE enrollment to European CE Mark within a single year, the covered stent segment is widening its addressable indication set faster than the underlying PAD patient population is growing, so indication breadth is becoming as important to market share as base disease prevalence.

The global iliac stent market size was USD 1.00 Billion in 2025 and is expected to register a revenue CAGR of 5.2% during the forecast period.Iliac stents are endovascular devices placed within the common iliac artery, external iliac artery, and aortoiliac bifurcation to treat symptomatic peripheral artery disease including claudication, critical limb ischaemia, and aortoiliac occlusive disease.Market revenue growth is supported by the growing global prevalence of peripheral artery disease, with the Institute for Health Metrics and Evaluation documenting global PAD prevalence at approximately 1.52%, or nearly 113 million people, and annual incidence of approximately 10 million new cases.The commercial expansion of covered iliac stents followed Getinge's iCast covered stent system receiving FDA premarket approval in March 2023 for symptomatic iliac arterial occlusive disease, with Cook Medical assuming exclusive US sales, marketing, and distribution in March 2024.Endovascular devices account for 87.8% of aortoiliac occlusive disease treatment, reflecting the high proportion of PAD management now performed via stent-supported angioplasty rather than open surgical revascularisation.In July 2025, Getinge announced FDA approval of an expanded iCast indication as a bridging stent for treatment of aneurysmal disease in conjunction with an approved endograft, broadening the platform's commercial indication beyond peripheral artery occlusive disease.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a covered stent platform widens its addressable revenue every time it clears a new indication on the same underlying device construction, capturing an entirely different clinical use case without a new manufacturing investment.Once a covered stent has established FDA approval for iliac occlusive disease, extending that same platform to a bridging stent indication for aneurysmal disease captures a structurally different patient population, the endovascular aneurysm repair adjunct market, on the same underlying ePTFE-covered nitinol or stainless steel construction, so revenue compounds as the indication list widens around one physical device.As a result, demand and revenue share are concentrating around covered stent platforms with the broadest indication set spanning occlusive and aneurysmal disease, that hold the deepest multi-year clinical evidence, and the forecast tilts toward these multi-indication platforms rather than single-indication bare metal alternatives.For instance, BD advanced its Revello Vascular Covered Stent from completed enrollment in the iliac artery patient cohort of its pivotal AGILITY IDE study in November 2025 to CE Marking in Europe in March 2026, launching the device at the LINC 2026 congress in Germany within roughly four months of the US trial milestone.These are some of the key factors driving revenue growth of the market.

Because escalating adoption of drug-eluting stents and drug-coated balloons in peripheral artery lesions creates competition with bare metal iliac stents in lesion types where sustained drug elution may reduce restenosis rates, this constrains bare metal stent volume particularly in external iliac artery lesions with known mid-term restenosis risk.

Covered stent reimbursement complexity is a second constraint, as procurement approval timelines in European public healthcare systems limit commercial acceleration of covered stent adoption beyond high-volume vascular surgery reference centres.

Complex aortoiliac bifurcation stenting technique requirements are a third constraint, since long procedure times and specialist training requirements for kissing stent techniques and IBD-type reconstruction limit procedure volume to high-volume vascular and interventional radiology centres.

These factors substantially limit iliac stent market growth over the forecast period.

The clearest driver of demand is the covered stent segment's expansion from a single occlusive-disease indication into a broader set of clinical applications. A covered stent platform only captures the aneurysmal bridging market if its underlying ePTFE-covered construction has already proven durable enough for FDA approval in the more demanding occlusive disease indication, and Getinge's iCast, with five-year clinical evidence supporting covered stent durability, cleared exactly that bar before pursuing the bridging stent expansion. Getinge announced FDA premarket approval for the iCast in March 2023, following over 20 years of commercial availability outside the US as the Advanta V12 covered stent system, with Cook Medical assuming exclusive US distribution in March 2024. In July 2025, Getinge announced FDA approval of an expanded iCast indication as a bridging stent for treatment of aneurysmal disease in conjunction with an approved endograft, with Getinge stating the expanded scope extends treatment to more patients. The effect on the market is that the covered stent segment is now addressing both occlusive and aneurysmal disease populations from a single approved platform, widening its addressable revenue without a new device development programme. These are some of the key factors driving revenue growth of the market.

The second driver is the sustained epidemiological growth in the patient population requiring iliac revascularisation. A structurally growing PAD patient population only translates into proportional device demand if endovascular treatment infrastructure keeps pace, and BD's international AGILITY study, evaluating its Revello Vascular Covered Stent, is specifically designed to expand the evidence base supporting that continued endovascular-first treatment pathway. BD completed enrollment in the iliac artery patient cohort of its pivotal AGILITY IDE study in November 2025, and received CE Marking for the Revello Vascular Covered Stent in March 2026, launching the device at the LINC 2026 congress in Germany. In January 2026, W.L. Gore received FDA approval for its Viabahn Fortegra Venous Stent, the first device approved for deep venous disease in the inferior vena cava, iliac, and iliofemoral veins, extending covered stent competition into the adjacent venous disease category. The effect on the market is that the covered iliac stent competitive field is broadening beyond Getinge's iCast to include BD's Revello and Gore's Fortegra, intensifying both arterial and venous covered stent competition simultaneously. These are some of the key factors driving revenue growth of the market.

“BD advanced its Revello Vascular Covered Stent from completed AGILITY trial enrollment to European CE Marking and LINC 2026 congress launch within roughly four months, confirming covered iliac stenting has become a genuinely multi-vendor competitive category.”

However, the iliac stent market faces severe adoption constraints from drug-eluting stent and drug-coated balloon competition, covered stent reimbursement complexity in European public healthcare systems, and complex aortoiliac bifurcation stenting technique requirements.

Because escalating adoption of drug-eluting stents and drug-coated balloons in peripheral artery lesions creates competition with bare metal iliac stents where sustained drug elution may reduce restenosis rates, this is particularly acute in external iliac artery lesions with known mid-term restenosis risk.

Covered stent reimbursement complexity is a second constraint, as European national health systems with cost-constrained procurement processes favour lower-cost bare metal alternatives for straightforward common iliac artery stenosis indications.

Complex aortoiliac bifurcation stenting technique requirements are a third constraint, limiting procedure volume to high-volume vascular and interventional radiology centres with advanced iliac intervention programmes.

These factors substantially limit iliac stent market growth over the forecast period.

Based on type, the global iliac stent market is segmented into self-expanding and balloon-expandable iliac stents. Self-expanding iliac stents account for the largest revenue share at approximately 65% of 2025 market revenue. Self-expanding nitinol iliac stents are preferred for external iliac artery lesions and longer common iliac artery lesions, where external elastic recoil provides superior conformability to tortuous iliac anatomy. Balloon-expandable iliac stents retain clinical preference for aortoiliac bifurcation ostial lesions, where precise deployment at the aortic bifurcation requires the non-foreshortening, exact positioning characteristics of balloon-expandable stent designs.

Based on artery lesion, the global iliac stent market is segmented into common iliac artery lesions, external iliac artery lesions, and aortoiliac bifurcation lesions. Common iliac artery lesions accounted for approximately 60.5% of market revenue, driven by the high prevalence of atherosclerotic stenosis in diabetic, hypertensive, and hyperlipidaemic patients. Asia Pacific is expected to register the fastest revenue CAGR over the forecast period, driven by increasing PAD awareness and expanding endovascular vascular intervention infrastructure at Chinese and Indian hospital catheterisation laboratories.

Based on regional analysis, North America accounted for approximately 43% of global iliac stent revenue in 2025, with the US market estimated at approximately USD 216.8 Million in 2023. North America's leadership reflects the aging US population with rising PAD risk factors, favourable CMS reimbursement for endovascular peripheral artery revascularisation, and the commercial presence of Abbott, Medtronic, BD, Boston Scientific, Cook Medical, Getinge, and W.L. Gore as the primary US iliac stent manufacturers. The 2023 FDA commercial launch of the Getinge iCast covered stent system and Cook Medical's assumption of US distribution expanded the covered iliac stent market with a dedicated first FDA PMA-approved covered iliac stent.

The market in Europe is expected to register a steady revenue growth rate in the global iliac stent market over the forecast period.

Germany, France, the United Kingdom, and Italy represent the four largest national iliac stent markets in Europe. The Getinge Advanta V12 covered stent system, the international equivalent of the iCast, has maintained established clinical relationships at European vascular surgery accounts for over 20 years, and BD's Revello Vascular Covered Stent launched at the LINC 2026 congress in Germany following its March 2026 CE Marking. The European Society for Vascular Surgery guidelines support endovascular first-line intervention for TASC A, B, and selective C aortoiliac lesions, sustaining iliac stent procedure volume at European vascular units.

The market in Asia Pacific is expected to register the fastest revenue growth rate in the global iliac stent market over the forecast period.

Japan, China, South Korea, and India represent the four largest national iliac stent markets in Asia Pacific. China's Zylox-Tonbridge Medical Technology received NMPA approval for its peripheral venous stent system, reflecting the expanding Chinese domestic peripheral vascular stent regulatory approval landscape. The rising prevalence of type 2 diabetes and hypertension in China's aging population creates an expanding PAD patient population, with Chinese tier-1 hospital vascular surgery programmes expanding endovascular treatment capabilities.

Latin America and Middle East and Africa markets are expected to register moderate revenue growth rates in the global iliac stent market over the forecast period.

Brazil and Mexico represent the two largest national iliac stent markets in Latin America, with high diabetes and hypertension prevalence creating a significant PAD patient population. Saudi Arabia and the UAE represent the primary GCC markets, with the Saudi Vision 2030 hospital infrastructure expansion including vascular and endovascular intervention programme development.